Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Opdivo approved quickly for first hematological cancer

FDA granted accelerated approval to Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat classical Hodgkin's lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and treatment with Adcetris brentuximab vedotin. BMS said Opdivo is the first FDA-approved PD-1 inhibitor for a hematological malignancy.

The approval came well ahead of Opdivo's Sept. 1 PDUFA date in the indication, for which it has breakthrough therapy and Orphan Drug designations.

BMS markets Opdivo to treat metastatic non-small cell lung cancer (NSCLC), advanced renal cell carcinoma (RCC) and melanoma. Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) market Adcetris, an antibody-drug conjugate (ADC) composed of an anti-CD30 mAb and monomethyl auristatin E (MMAE).

Published on Tuesday, May 17, 2016

Source: http://www.biocentury.com/

0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote